631 results on '"Schwartz, Marc"'
Search Results
2. Clinical and sociodemographic factors associated with digital health literacy in patients with non-Hodgkin lymphoma or colorectal carcinoma.
3. Randomized phase II trial of pembrolizumab/lenvatinib (P+L) +/- responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL).
4. Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC).
5. Quality of Life for Patients with Sporadic Small Vestibular Schwannomas Following Middle Fossa Craniotomy
6. Surgery for Crohn’s Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts
7. Clinical Outcomes of Salvage Microsurgical Resection After Radiation Therapy for Sporadic Vestibular Schwannomas
8. Treatment of Elderly Patients with Acute Lymphoblastic Leukemia
9. Real-world differences in dosing and clinical utilization of OnabotulinumtoxinA and AbobotulinumtoxinA in the treatment of upper limb spasticity
10. Framework for in vivo T cell screens
11. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
12. Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care
13. Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy
14. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
15. Patient Persistence to OnabotulinumtoxinA Treatment for Overactive Bladder Using A Reduced-Injection-Site Paradigm: A Retrospective Chart Review Study
16. Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors
17. Comparison of Postoperative Outcomes in Cystic Versus Solid Vestibular Schwannoma in a Multi-institutional Cohort
18. Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives
19. Memory deficit following resection of an intraventricular myxoid glioneuronal tumor impinging on the bilateral fornix: A case report
20. Mediational roles of stress-coping factors in the relationship between patient-perceived communication quality and physical functioning: racial difference between Chinese and Non-Hispanic White American breast cancer survivors
21. Human STING is a proton channel
22. Socioeconomic Disparities in the Pursuit of Care at a High-Volume Institution for Surgical Resection of Vestibular Schwannomas
23. P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
24. Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia
25. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease
26. The Effect of Immediate Microsurgical Resection of Vestibular Schwannoma on Hearing Preservation
27. Addressing disparities in the uptake of genetic counseling and testing in African American women; rationale, design and methods
28. Real-World Clinical Utilization Differences of onabotulinumtoxinA and abobotulinumtoxinA in Upper Limb Spasticity (P12-8.013)
29. Treating Upper Limb Spasticity With OnabotulinumtoxinA: Subgroup Analysis of US Practice Patterns From the ASPIRE Study (P12-8.012)
30. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse
31. Characteristics and Treatment Response to OnabotulinumtoxinA of Patients From CD-PROBE With Anterocollis and Retrocollis (P12-11.005)
32. Going the distance in acoustic neuroma resection: microsurgical outcomes at high-volume centers of excellence
33. Advancing health equity: A qualitative study assessing barriers and facilitators of implementing hereditary breast and ovarian cancer risk screening tools in community‐based organizations
34. Association Between Facility Surgical Volume and Excess Time in the Hospital After Surgical Resection of Vestibular Schwannomas
35. Sudden unexpected death from hydrocephalus due to cerebellopontine angle meningioma
36. Abstract OT3-14-01: A longitudinal investigation of sociocultural and behavioral influences on symptom management, biological response, and functioning among Chinese American and White female breast cancer survivors
37. Management of Neurofibromatosis Type 2-Associated Vestibular Schwannomas
38. Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
39. Going the Distance in Acoustic Neuroma Resection: Microsurgical Outcomes at High-Volume Centers of Excellence
40. ESCRT-dependent STING degradation inhibits steady-state and cGAMP-induced signalling
41. Audiometric Outcomes of Auditory Brainstem Implantation during Vestibular Schwannoma Resection: A Single-Institution Case Series
42. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor–Positive Breast Cancer
43. Real-World Experience with Low Dose Interleukin-2 for Children with Steroid Refractory Chronic Graft Vs Host Disease
44. Functional Gait Assessment in Geriatric Patients Following Vestibular Schwannoma Resection
45. Granuloma Presence at Initial Surgery Predicts Need for Repeat Surgery Independent of Rutgeerts Score in Crohn’s Disease
46. Cultural adaptations to a telephone genetic counseling protocol and booklet for Latina breast cancer survivors at risk for hereditary breast and ovarian cancer
47. OnabotulinumtoxinA Treatment of Upper Limb Spasticity: Analysis of US Practice Patterns From the ASPIRE Study
48. Spontaneous chronic subdural haematoma due to hypoplastic rostral superior sagittal sinus
49. Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia
50. Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.